These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34632716)

  • 1. Consensus Virtual Screening Identified [1,2,4]Triazolo[1,5-b]isoquinolines As MELK Inhibitor Chemotypes.
    Rácz A; Palkó R; Csányi D; Riedl Z; Bajusz D; Keserű GM
    ChemMedChem; 2022 Jan; 17(2):e202100569. PubMed ID: 34632716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel inhibitor discovery through virtual screening against multiple protein conformations generated via ligand-directed modeling: a maternal embryonic leucine zipper kinase example.
    Mahasenan KV; Li C
    J Chem Inf Model; 2012 May; 52(5):1345-55. PubMed ID: 22540736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth.
    Edupuganti R; Taliaferro JM; Wang Q; Xie X; Cho EJ; Vidhu F; Ren P; Anslyn EV; Bartholomeusz C; Dalby KN
    Bioorg Med Chem; 2017 May; 25(9):2609-2616. PubMed ID: 28351607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward the Validation of Maternal Embryonic Leucine Zipper Kinase: Discovery, Optimization of Highly Potent and Selective Inhibitors, and Preliminary Biology Insight.
    Touré BB; Giraldes J; Smith T; Sprague ER; Wang Y; Mathieu S; Chen Z; Mishina Y; Feng Y; Yan-Neale Y; Shakya S; Chen D; Meyer M; Puleo D; Brazell JT; Straub C; Sage D; Wright K; Yuan Y; Chen X; Duca J; Kim S; Tian L; Martin E; Hurov K; Shao W
    J Med Chem; 2016 May; 59(10):4711-23. PubMed ID: 27187609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based discovery of new maternal embryonic leucine zipper kinase inhibitors.
    Zhou S; Li GB; Luo L; Zhong L; Chen K; Li H; Jiang XJ; Fu Q; Long X; Bao JK
    Org Biomol Chem; 2018 Feb; 16(9):1489-1495. PubMed ID: 29411820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.
    Chung S; Suzuki H; Miyamoto T; Takamatsu N; Tatsuguchi A; Ueda K; Kijima K; Nakamura Y; Matsuo Y
    Oncotarget; 2012 Dec; 3(12):1629-40. PubMed ID: 23283305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells.
    McDonald IM; Grant GD; East MP; Gilbert TSK; Wilkerson EM; Goldfarb D; Beri J; Herring LE; Vaziri C; Cook JG; Emanuele MJ; Graves LM
    J Biol Chem; 2020 Feb; 295(8):2359-2374. PubMed ID: 31896573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening.
    Jung ME; Byun BJ; Kim HM; Lee JY; Park JH; Lee N; Son YH; Choi SU; Yang KM; Kim SJ; Lee K; Kim YC; Choi G
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2719-23. PubMed ID: 27106709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.
    Maes A; Maes K; Vlummens P; De Raeve H; Devin J; Szablewski V; De Veirman K; Menu E; Moreaux J; Vanderkerken K; De Bruyne E
    Blood Cancer J; 2019 Nov; 9(12):87. PubMed ID: 31740676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel carbon-11 radiolabeled maternal embryonic leucine zipper kinase inhibitor for PET imaging of triple-negative breast cancer.
    Tang R; Gai Y; Li K; Hu F; Gong C; Wang S; Feng F; Altine B; Hu J; Lan X
    Bioorg Chem; 2021 Feb; 107():104609. PubMed ID: 33454507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triazolopyridazine LRRK2 kinase inhibitors.
    Franzini M; Ye XM; Adler M; Aubele DL; Garofalo AW; Gauby S; Goldbach E; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong A; Ren Z
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1967-73. PubMed ID: 23454015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational insights into the binding of IN17 inhibitors to MELK.
    Harger M; Lee JH; Walker B; Taliaferro JM; Edupuganti R; Dalby KN; Ren P
    J Mol Model; 2019 May; 25(6):151. PubMed ID: 31069524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Keto-3-cyano-2,4-diaminothiophenes as selective maternal embryonic leucine zipper kinase inhibitors.
    Boutard N; Sabiniarz A; Czerwińska K; Jarosz M; Cierpich A; Kolasińska E; Wiklik K; Gluza K; Commandeur C; Buda A; Stasiowska A; Bobowska A; Galek M; Fabritius CH; Bugaj M; Palacz E; Mazan A; Zarębski A; Krawczyńska K; Żurawska M; Zawadzki P; Milik M; Węgrzyn P; Dobrzańska M; Brzózka K; Kowalczyk P
    Bioorg Med Chem Lett; 2019 Feb; 29(4):607-613. PubMed ID: 30626559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based virtual screening of chemical libraries as potential MELK inhibitors and their therapeutic evaluation against breast cancer.
    Das A; Prajapati A; Karna A; Sharma HK; Uppal S; Lather V; Pandita D; Agarwal P
    Chem Biol Interact; 2023 May; 376():110443. PubMed ID: 36893906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
    Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
    Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel pyruvate dehydrogenase kinases inhibitors by screening of an in-house small molecule library for anti-lung cancer therapeutics.
    Guo F; Zhao S; Li X
    Bioorg Med Chem Lett; 2019 Jan; 29(2):291-296. PubMed ID: 30470491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of Maternal Embryonic Leucine Zipper Kinase (MELK) in complex with dorsomorphin (Compound C).
    Rembacz KP; Zrubek KM; Golik P; Michalik K; Bogusz J; Wladyka B; Romanowska M; Dubin G
    Arch Biochem Biophys; 2019 Aug; 671():1-7. PubMed ID: 31108049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of new NIK inhibitors by discriminatory analysis-based molecular docking and biological evaluation.
    Cheng G; Mei XB; Yan YY; Chen J; Zhang B; Li J; Dong XW; Lin NM; Zhou YB
    Arch Pharm (Weinheim); 2019 Jul; 352(7):e1800374. PubMed ID: 31116887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a series of 1H-pyrrolo[2,3-b]pyridine compounds as potent TNIK inhibitors.
    Yang B; Wu Q; Huan X; Wang Y; Sun Y; Yang Y; Liu T; Wang X; Chen L; Xiong B; Zhao D; Miao Z; Chen D
    Bioorg Med Chem Lett; 2021 Feb; 33():127749. PubMed ID: 33340663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.